Form 4: ResMed Executive Ghoshal Exercises Options and Sells Shares
SEC Form 4 Filing
Kaushik Ghoshal, Chief Commercial Officer, SaaS at ResMed, exercised stock options and sold shares on September 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 12, 2024, Kaushik Ghoshal, Chief Commercial Officer, SaaS at ResMed Inc., executed transactions involving ResMed common stock.
- Ghoshal exercised options to acquire 5,000 shares at a price of $101.64 per share.
- Simultaneously, Ghoshal sold 5,000 shares at a price of $252.56 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on April 29, 2024.
- Following these transactions, Ghoshal directly owns 21,788 shares of ResMed common stock and 4,260 ResMed Common Stock Options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock transactions by an executive. The transactions themselves don't inherently indicate positive or negative sentiment about the company's future.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to assess management's perspective on the company's value and prospects. These transactions are not necessarily indicative of the company's performance or future outlook.
Comparison to Industry Standards
- Executive stock option exercises and sales are common practice in publicly traded companies like ResMed.
- Companies such as Philips, Medtronic, and Stryker also have executives who regularly exercise stock options and sell shares as part of their compensation packages.
- The use of Rule 10b5-1 plans is a standard method to avoid accusations of insider trading, allowing executives to sell shares at predetermined times and prices.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/14/2018 | Date options first became exercisable. |
| 04/29/2024 | Date the Rule 10b5-1 plan was adopted. |
| 09/12/2024 | Date of the stock option exercise and share sale. |
| 09/13/2024 | Date of the signature on the Form 4 filing. |
| 11/14/2025 | Expiration date of the ResMed Common Stock Options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.